NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.2 Corticosteroids and other immunosuppressants > Ocrelizumab for treating primary progressive multiple sclerosis - NICE TAG TA585

Ocrelizumab for treating primary progressive multiple sclerosis - NICE TAG TA585

Recommendations

1.1 Ocrelizumab is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. It is recommended only if the company provides it according to the commercial arrangement.

Why the committee made these recommendations

There are currently no disease-modifying treatments available for primary progressive multiple sclerosis. Results of 1 clinical trial show that ocrelizumab can slow the worsening of disability, although the size and duration of this effect are uncertain.

Given the unmet clinical need, the most plausible cost-effectiveness estimates for ocrelizumab at the agreed price compared with best supportive care alone are in the range that NICE considers an acceptable use of NHS resources. Because of this, ocrelizumab is recommended for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults.

https://www.nice.org.uk/guidance/ta585

Site by Devopa
© Copyright 2019 NHS. All rights reserved.